Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01259128 · ClinicalTrials.gov registry record · Phase 3
Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia
A Phase 3 study, sponsored by Serenity Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
NCT01259128 is a Phase 3 study that has completed, run by Serenity Pharmaceuticals. The registered enrollment target is 32 participants.
The verdict
NCT01259128, a Phase 3 study, has completed, sponsored by Serenity Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if SER120 nasal spray is well tolerated in 75 years or older nocturic patients.
Interventions
- DRUG SER120 Nasal Spray 500 ng/day
- DRUG SER120 nasal spray 750 ng/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01259128
The ClinicalTrials.gov registry entry for NCT01259128 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Serenity Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SER120 Nasal Spray 500 ng/day is the first listed.
NCT01259128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01259128 about?
NCT01259128 is a clinical study titled "Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia". The purpose of this study is to determine if SER120 nasal spray is well tolerated in 75 years or older nocturic patients.
What is the current status of trial NCT01259128?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2010-04. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01259128?
The interventions under investigation include: SER120 Nasal Spray 500 ng/day (DRUG), SER120 nasal spray 750 ng/day (DRUG).
Who is sponsoring clinical trial NCT01259128?
This trial is sponsored by Serenity Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.